Novo Nordisk built an entire phase 3 program, branded CagriSema, around the idea of bolting an amylin analog onto a GLP-1 agonist
Fasting, calorie restriction, and exercise robustly activate these pathways and confer broad metabolic benefits
Muscle-Tendon Junction Research on injuries at the muscle-tendon junction (a common injury site in athletes) showed BPC-157 promoted coordinated healing of both tissue types, maintaining the integrity of this critical interface
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis
Closing: The Clinical Bottom Line on What Is BPC-157 BPC-157 is a synthetic signaling peptide with a narrow, high-confidence clinical use case: accelerating soft tissue repair, calming gut lining inflammation, and supporting joint recovery in patients who have stalled with standard care
This is a CagriSema, as you know, a combination of the GLP-1 receptor agonist semaglutide plus the long-acting amylin cagrilintide, so two different mechanisms of actions, two different compounds both affecting appetite in an additive way
